ArticleBrain and behavior2025
Prevalence and Correlates of Depression and Suicidal Ideation Across Stages 0-4 of Cardiovascular-Kidney-Metabolic Syndrome.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and Correlates of Depression and Suicidal Ideation Across Stages 0-4 of Cardiovascular-Kidney-Metabolic Syndrome.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe American Heart Association (AHA) recently introduced the cardiovascular-kidney-metabolic (CKM) syndrome framework to improve cardiovascular health management. However, evidence on the prevalence of depression and suicidal ideation (SI) across distinct CKM stages is limited.
methodsThis cross-sectional study analyzed data from 10,519 US adults participating in the National Health and Nutrition Examination Survey (NHANES) 2007 to 2018. Depression and SI were assessed using the nine-item Patient Health Questionnaire (PHQ-9). CKM syndrome stages were classified as: Stage 0 (absence of risk factors); Stage 1 (excess/dysfunctional adiposity); Stage 2 (metabolic risk factors or moderate-to-high-risk CKD); Stage 3 (subclinical cardiovascular disease [CVD] or its risk equivalents); and Stage 4 (clinical CVD). Weighted statistical analyses were conducted to account for the complex sampling design of NHANES and obtain nationally representative estimates.
resultsThe prevalence of depression increased progressively with advancing CKM syndrome stages: 10.9% (Stage 0), 13.9% (Stage 1), 19.0% (Stages 2 and 3 combined), and 30.0% (Stage 4) (p for trend < 0.001). In contrast, the overall prevalence of SI remained relatively stable across stages (2.9%-4.9%; p for trend = 0.25). However, SI was significantly elevated specifically among females (8.0%) and Hispanic individuals (10.3%) in Stage 4. Stage-specific correlates of depression varied, encompassing socioeconomic and lifestyle factors in early stages and incorporating additional complex biomedical factors in advanced stages. Depression was consistently and strongly associated with SI across all stages. Models combining stage-specific correlates demonstrated moderate to good discrimination (area under the curve [AUC]: 0.650-0.748 for depression; 0.734-0.869 for SI).
conclusionsAdvancing stages of CKM syndrome are associated with a significantly increased prevalence of depression, highlighting the critical need for integrating mental healthcare into CKM management. The identification of stage-specific correlates provides valuable insights for developing targeted screening and intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.